April 29 Quick Takes: Illumina pushes back on EC review of Grail deal, donates tools to global initiative; plus Zhaoke, Sera, Ardelyx, Protalix-Chiesi, Moderna, Phathom, Tris-Park and more

Following last month’s 4-0 vote by the FTC to challenge Illumina’s pending $7.1 billion acquisition of Grail, the company announced that it filed an action in the General Court of the European Union requesting an annulment of the EC’s decision to review the deal. 

Also this week, Illumina Inc. (NASDAQ:ILMN) said it will donate $60 million in sequencing capabilities over five years to a global pathogen genomics initiative partnered with the Bill & Melinda Gates Foundation and other public and private entities. The program will build on the Africa Pathogen Genomics Initiative announced in October, with an initial focus on South Asia. ...